Express delivery and free returns within 21 days

Wednesday, July 6, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

New Study Finds Procedures Treating Spinal Fractures Associated with Reduction in Opioid Use & Decreased Payer Costs

Study shows 57.1% of patients discontinued or reduced oral opioid prescription refills post-procedure and exhibited a decrease in payer costs

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases elimination of oral opioids, and decrease in payer costs following balloon kyphoplasty (BKP) or vertebroplasty (VP) procedures in patients suffering from spinal fractures, known as vertebral compression fractures (VCF).1

- Advertisement -

This study, sponsored by Medtronic, is the first published study to evaluate the effect of BKP and VP on opioid reduction as a primary outcome.

An estimated 800,000 VCFs occur in the United States every year.2 They are associated with debilitating pain, spinal deformity, increased mortality, and increased healthcare-resource utilization in elderly patients.3-5 VCFs are often treated with conservative medical management (CMM), including bed rest, back bracing, and prescription oral opioids. These treatments have been shown in clinical studies to have limited effectiveness in reducing pain and improving function long-term compared to interventional treatments like BKP and VP.6-10

Both BKP and VP treat painful pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions. The goal of BKP and VP is to relieve pain and stabilize VCFs. BKP is supported by a robust body of evidence showing important clinical benefits compared to conventional medical management, which include better pain relief and improved quality of life and function.6,7,8,9 These procedures have also been shown to reduce the need for prescription opioids.8

This study, titled, “Trends in opioid use following balloon kyphoplasty  or vertebroplasty for the treatment of vertebral compression fractures,” evaluated the effect of BKP or VP on post-procedure opioid prescription fills and payer costs in patients with VCF through a retrospective claims analysis of a large, nationally representative insurance-claims database. Clinical characteristics, opioid-prescription patterns, and payer costs for subjects who underwent either BKP or VP to treat VCF were evaluated beginning six months prior to surgery through seven-months follow-up that included a 30-day post-operative medication washout period to account for the management of post-surgical pain.

The analysis found that 57.1% of patients decreased use of oral opioids, with 48.7% discontinuing use altogether and 8.4% reducing prescription refills post-procedure when compared to the six months prior to the procedure. Additionally, patients who decreased or discontinued opioid prescription fills post-procedure significantly reduced total payer costs over six-month follow-up relative to baseline, with average savings of $6,759.1 Conversely, patients who maintained, increased, or newly started opioids in follow-up slightly increased their payer costs ($160) relative to baseline.

“Our observations are consistent with the existing body of evidence showing a decrease in opioid use following balloon kyphoplasty or vertebroplasty procedures to treat spinal fractures, said Dr. Joshua Hirsch, corresponding author and practicing physician at Massachusetts General Hospital. “Previous studies drew their conclusions from small study populations and clinical trials that were not necessarily designed to measure opioid use as a primary outcome. This study is unique in that it evaluates the impact of these procedures on opioid prescription fills as primary outcome, using a larger, real-world study population.”

“Given the current opioid epidemic and ongoing pain management crisis, we believe there is a need to better explore solutions that effectively address pain and support the elimination of oral opioids,” said Anu Codaty, vice president and general manager, Interventional Pain within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “Based on the findings of this study, there may be an added benefit for this patient population in reducing opioid-based harms.”

Medtronic has more than a 40-year history of developing innovative medical devices that have been shown to alleviate pain in different disease states, including BKP, VP, Spinal Cord Stimulation and Targeted Drug Delivery.12 These therapies may help patients manage their pain without the use of oral opioids.

SourceMedtronic
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img

Other News of Interest

Executives on the Move

By using this website you agree to accept Medical Device News Magazine Privacy Policy